A unique immunomodulatory apheresis procedure that combines leukapheresis, photoactivation of a psoralen compound, and UVA irradiation to selectively induce apoptosis in pathological lymphocytes. ECP does not cause generalized immunosuppression, making it particularly valuable in conditions where preserving immune function is critical.
Patients receiving oral 8-methoxypsoralen (8-MOP) must avoid direct sunlight and UV light exposure for a minimum of 24 hours after taking the medication. Psoralen compounds are potent photosensitizers — UV exposure during this window can cause severe sunburn, blistering, and ocular damage. Patients must wear UV-protective sunglasses (wrap-around style) and protective clothing when outdoors. This warning applies even on cloudy days, as UV radiation penetrates cloud cover. Patients using the extracorporeal 8-MOP delivery system (UVADEX®) have significantly lower systemic psoralen levels and reduced photosensitivity risk, but sun protection is still recommended on the day of treatment.
Extracorporeal Photopheresis is a three-step process. First, a leukapheresis procedure collects a buffy coat fraction enriched with mononuclear cells (lymphocytes and monocytes) from the patient's blood. The remaining cellular components — red blood cells and platelets — are returned to the patient throughout the procedure.
In the second step, the collected mononuclear cell fraction is mixed with a photoactivatable compound called 8-methoxypsoralen (8-MOP, methoxsalen). 8-MOP intercalates into DNA base pairs but remains inert until activated by light.
In the third step, the 8-MOP–treated cell suspension is exposed to a measured dose of UVA light (320–400 nm wavelength) within the apheresis device. UV activation causes 8-MOP to form covalent crosslinks with DNA pyrimidine bases, triggering irreversible DNA damage and programmed cell death (apoptosis) in the irradiated lymphocytes. The treated cells are then reinfused into the patient.
The reinfusion of apoptotic lymphocytes is believed to trigger a tolerogenic immune response — dendritic cells phagocytose the dying cells and present their antigens in a regulatory context, shifting the immune balance toward tolerance rather than attack. This mechanism explains why ECP can suppress pathological immune responses (as in GvHD or autoimmune disease) without causing broad immunosuppression.
8-MOP Delivery Methods: 8-MOP can be administered orally (patient takes capsules 2 hours before the procedure) or directly into the extracorporeal circuit (UVADEX® injectable methoxsalen). Extracorporeal delivery results in much lower systemic drug levels and significantly reduces photosensitivity risk compared to oral administration.
Selective Immunomodulation: ECP's key advantage is that it modulates immune responses without causing global immunosuppression. Patients maintain their ability to fight infections and mount normal immune responses, which is critical for transplant recipients and immunocompromised patients.
Response Timeline: Unlike TPE or RBCX which produce rapid changes, ECP's immunomodulatory effects develop gradually. Clinical response may not be apparent for 3–6 months. Patients and clinicians must understand this delayed response profile to avoid premature discontinuation.
| Condition | Category | Grade | Notes |
|---|---|---|---|
| Cutaneous T-Cell Lymphoma (CTCL) — Erythrodermic | I | 1B | FDA-approved indication; best response in erythrodermic Sézary syndrome |
| Graft-vs-Host Disease — Chronic (Skin-Predominant) | I | 1B | Steroid-refractory cGvHD; skin, oral, and ocular manifestations respond best |
| Graft-vs-Host Disease — Acute | II | 2B | Steroid-refractory acute GvHD; adjunct to standard immunosuppression |
| Cardiac Allograft Rejection — Prophylaxis | II | 2B | Adjunct immunosuppression in cardiac transplant recipients |
| Systemic Sclerosis (Scleroderma) | II | 2C | Skin softening and disease stabilization in progressive disease |